The Cervin Group aims to improve outcomes for patients who suffer from debilitating chronic sinus and ear infections. A primary focus of the lab is to gather new knowledge on the microbiome of the sinus, ear, nose and throat during health and to understand how the biome differs in patients with chronic sinus and ear infections. The Cervin Group is also working to develop microbiome therapies that will reduce problematic infections in the sinus and ears.

Exploring the Sinus Microbiome

The Cervin group is investigating the microbiome of the nose, sinus and throat of individuals with healthy sinuses and chronic sinus infections to gather new information on the sinus microbiome. Through this work we have identified a number of friendly bacteria (commensals) from healthy individuals that have the ability to reduce the growth of bacterial strains associated with chronic sinus infections in vitro.

Testing a Microbiome Therapy for Chronic Rhinosinusitis

Through a collaboration with Winclove Probiotics and ENT Technologies the Cervin Group is developing a microbiome therapy nasal spray to treat chronic rhinosinusisits. Preparations are currently underway to test this treatment in humans. 

A Microbiome Therapy to Prevent Otitis Media in Aboriginal and Torres Straight Island Children

The Aboriginal and Torres Strait Island population have some of the highest rates of Otitis Media in the world. In collaboration with The Deadly Ears Program the Cervin Group has started a research program exploring the normal bacterial flora in the upper airway in the indigenous population and how it contributes to maintaining health. The aim of this study is to prevent Otitis Media in Aboriginal and Torres Strait Islander children by supplementing the airway with a microbiome therapy. 

For further information download the study brochure.

Reducing troublesome nasal tissue with Radiofrequency Ablation in an Australian hospital setting

Radiofrequency ablation is a well-established, effective treatment for reducing troublesome nasal tissue that is offered to patients as an alternative to surgery in the United States and the United kingdom, however, this treatment is rarely used in Australia. This study aims to assess the radiofrequency ablation (RFA) treatment in an Australian hospital setting.


  • Dr Seweryn Bialasiewicz, University of Queensland
  • The Deadly Ears Program, Queensland Health
  • The Garnett Passe and Rodney Williams Memorial Foundation, Australia
  • Professor Flavia Huygens, Queensland University of Technology
  • Royal Brisbane and Women’s Hospital
  • ENT Technologies


  • Dr Eva Grahn Hakansson
  • Dr Anders Maretnsson
  • Dr Charlotte Simark Mattson
  • Dr Kristian Roos
  • Lund University, Sweden
  • Winclove Probiotics

  • An exploratory safety study of 480 biomedical mometasone furoate sinus drug depot (MFSDD) in adult patients with chronic sinusitis.
  • A randomized, double­blind, 52­week, placebo controlled efficacy and safety study of dupilumab, in patients with bilateral nasal polyposis on a background therapy with intranasal corticosteroids.
  • Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Doomadgee in Queensland’s Gulf Country, and Mareeba on the Atherton Tablelands, are worlds away from the Herston research laboratory of Professor Anders Cervin.